These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 27660164

  • 1. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M, Kano M, Itagaki K, Sekiryu T.
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, Okada AA, Iida T, Sekiryu T.
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [Abstract] [Full Text] [Related]

  • 3. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK, Faber RT, Moe MC.
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration.
    Haga A, Kawaji T, Ideta R, Inomata Y, Tanihara H.
    Acta Ophthalmol; 2018 May; 96(3):e393-e398. PubMed ID: 29220114
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept.
    Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, Sakaguchi H, Nishida K.
    Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2559-2569. PubMed ID: 31482277
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH, Kim CG, Lee DW, Yoo SJ, Lew YJ, Cho HJ, Kim JY, Lee SH, Kim JW.
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT study group.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
    [Abstract] [Full Text] [Related]

  • 18. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
    Calvo-Gonzalez C, Reche-Frutos J, Fernández-Vigo JI, Donate-López J, Serrano-García I, Fernández-Pérez C.
    Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.